R&D News | pharmaphorum

News

Sanofi has bolstered its rare disease business with an agreement to buy Blueprint Medicines and blockbuster-in-waiting Ayvakit for ASM.

News

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).

News

Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.

News

Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in the BREAKWATER trial, setting up full FDA approval.

News

Summit Therapeutics thinks new data on PD-1xVEGF drug ivonescimab may support FDA approval, despite a survival miss.

News

Astellas was the first company to bring a drug against the claudin target CLDN18.2 to market, and has now added another to its cancer pipeline.